Odyssey Therapeutics
BOSTON, MA · Founded 2021 · CIK 0001882782 · Biotech · Private
Small molecule therapeutics for autoimmune and inflammatory diseases
odysseytx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $571M
- 4 Form D · Dec 2025
- 10 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 1 granted · 39 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $91,629,837 | |
| Private capital raised | Form D · SEC | $168,009,933 | |
| Private capital raised | Form D · SEC | $97,130,000 | |
| Private capital raised | Form D · SEC | $214,025,200 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1124 | Kriya Therapeutics | — | $769M |
| 1125 | VERSATOPE THERAPEUTICS, INC. | — | — |
| 1126 | Inhibrx, Inc. | — | $669M |
| 1127 | Odyssey Therapeutics | — | $571M |
| 1128 | Moderna | — | $556M |
| 1129 | Mariana Oncology | — | — |
| 1130 | OMVAX, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Charles BaumDirector
- Chuck BaumDirector
- M. BaumDirector
- Jill CarrollDirector
- Shelley ChuDirector
- Gary GlickDirector · Executive Officer
- Carl GordonDirector
- Jason HaasExecutive Officer
- Paulina HillDirector
- Lorence KimDirector
- Jeffrey LeidenDirector
- Nan LiDirector
- Carolyn NgDirector
- Valerie OdegardDirector
- Ksenija PavleticDirector
- Ian SmithDirector
- lan SmithDirector
- Nia TatsisDirector
- Timothy WalbertDirector
Patents
- Inhibitors Of RIPK2 And Medical Uses Thereofapplication
- Inhibitors Of RIPK2 And Medical Uses Thereofapplication
- Inhibitors Of RIPK2 And Medical Uses Thereofgranted
- ANTI-TNFR2 Antigen-binding Proteins And Uses Thereofapplication
- Multispecific Molecules Binding TNFR2 And CD25 And Uses Thereofapplication
- ANTI-CD25 Antigen-binding Proteins And Uses Thereofapplication
- Anti-thymic Stromal Lymphopoietin (tslp) Antigen-binding Proteins And Uses Thereofapplication
- Antigen-binding Proteins Against Serum Albumin And Uses Thereofapplication
- Inhibitors Of RIPK2 And Uses Thereofapplication
- Crystalline Forms Of RIPK2 Inhibitorapplication
- Multispecific Molecules Binding TRAILR2 And CDH17 And Uses Thereofapplication
- Multispecific Molecules Binding TRAILR2 And CDH17 And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.